WTEC Panel Report on Tissue Engineering Research
Autor Larry V. McIntireen Limba Engleză Hardback – 3 feb 2003
Preț: 1297.60 lei
Preț vechi: 1365.89 lei
-5% Nou
Puncte Express: 1946
Preț estimativ în valută:
248.33€ • 257.95$ • 206.28£
248.33€ • 257.95$ • 206.28£
Carte tipărită la comandă
Livrare economică 03-17 februarie 25
Preluare comenzi: 021 569.72.76
Specificații
ISBN-13: 9780124841505
ISBN-10: 0124841503
Pagini: 268
Dimensiuni: 152 x 229 x 18 mm
Greutate: 0.56 kg
Ediția:New.
Editura: ELSEVIER SCIENCE
ISBN-10: 0124841503
Pagini: 268
Dimensiuni: 152 x 229 x 18 mm
Greutate: 0.56 kg
Ediția:New.
Editura: ELSEVIER SCIENCE
Cuprins
Foreword List of Figures List of TablesExecutive Summary1. Introduction Background: The Significance of Tissue Engineering History of Tissue Engineering Promise of Tissue Engineering Other Applications Emerging Industry of Tissue Engineering Objectives of the WTEC Study Scope and Methodology Vision for the Future Acknowledgements References 2 Biomaterials Introduction U.S. R&D Activities Japanese R&D Activities European R&D Activities Summary References 3 Cells Introduction Analysis of Current State of the Art and Factors Influencing Progress Control of Cell Proliferation and Differentiation U.S. R&D Activities Background Current Efforts Future Position R&D Activities in Europe Japan Summary References4 Biomolecules Introduction Gene Transfer Angiogenic Factors/Growth Factors Differentiation Factors Bone Morphogenic Proteins References 5 Cell-Based Technologies: Non-Medical Applications Introduction Overview of R&D Activities Summary 6 Engineering Design Aspects of Tissue Engineering Introduction Bioreactor Technology Preservation of Cells and Engineered Tissues Mass Transport Issues Following Implantation Biomechanics Issues Summary References 7 Informatics and Tissue Engineering Introduction Informatics Components That Will Ultimately Support Tissue Engineering U.S. R&D Activities European R&D Activities Japanese R&D Activities Summary References 8 Legal and Regulatory Issues Introduction FDA Regulation Other Considerations Relevant to Engineered Tissues Regulation of Pharmaceutical/Medical Human Tissue Products in Europe Regulation of Pharmaceutical/Medical Human Tissue Products in Japan Conclusion ReferencesAppendices A. Biographies of Panelists B. Site Reports—Europe bwA, Aachen Centre of Competence: Biomaterials Cell Lining GmbH Berlin Workshop ERA Consulting (UK), Ltd ETH Zurich European Agency for the Evaluation of Medicinal Products (EMEA) European Molecular Biology Laboratory (EMBL) German Cancer Research Center (DKFZ) German Heart Institute Humboldt University of Berlin, Charite Biomaterial and Tissue Repair Laboratory (INSERM) Imperial College of Science, Technology and Medicine Imperial College of Science, Technology and Medicine University of Glasgow IsoTis (Technical Report) IsoTis (Regulatory Report) Kirchhoff Institute of Physics (KIP) Manchester University Max Planck Institute for Polymer Research MeVis Smith & Nephew Group Research Centre University of Freiburg University of Koln University of Regensburg University of Twente C. Appendix C. Site Reports-Japan Hokkaido University Japan Tissue Engineering Company, Ltd Keio University Kyoto University Kyushu University Nippon Telegraph and Telephone Corporation (NTT) Basic Research Laboratories Nagoya University National Cancer Center Research Institute National Institute for Advanced Interdisciplinary Research (NAIR) National Institute of Bioscience and Human Technology Institute of Physical and Chemical Research (RIKEN) Cell Bank Tokyo Institute of Technology Tokyo Women's Medical University University of Tokyo University of Tsukuba D. Summary of the June 2000 U.S. Review Workshop E. The Federal Investment in Tissue Engineering